Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sleep Blinding Psilocybin feasibility study
ISRCTN10648713Phase 2Recruiting
- Sponsor
- King's College London
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, single-blind trial of psilocybin, clonidine, daridorexant and diphenhydramine in major depressive disorder (MDD), sponsored by King's College London. Started Jun 2026; status: recruiting.
02
Drugs
psilocybinclonidinedaridorexantdiphenhydramine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN10648713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10648713.